Published Paper Details:

COVID 19 has affected humans in every possible way. According to the WHO Globally, as of 10:34am CEST, 9 July 2020, there have been 11,841,326 confirmed cases of COVID-19, including 544,739 deaths. Most affected regions include America followed by Europe. Chloroquine and hydroxychloroquine are commonly prescribed worldwide. When used for malaria prophylaxis, chloroquine is generally administered at a dose of 500 mg per week starting 2 weeks before and continuing for up to 8 weeks following endemic exposure. Long-term use can be considered for the treatment of chronic autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus. Hydroxychloroquine is typically prescribed as a 400 mg weekly dose when used for malaria chemoprophylaxis and as a 200 to 400 mg daily dose in patients with systemic lupus erythematosus or with rheumatoid arthritis on 17 June 2020, WHO announced that the hydroxychloroquine (HCQ) arm of the Solidarity Trial to find an effective COVID-19 treatment was being stopped. This review article discuss historical perspective and development of chloroquine analogues, current research work on chloroquine analogue, advance treatment used for the treatment of the COVID19 and new drugs as well as various test available for the COVID 19.